Nuo Therapeutics’ Aurix® System Added To Wound Care Formulary Of Wound Care Advantage
HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) — Nuo Therapeutics, Inc. (OTCQB:AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage (WCA), the nation’s leading wound care consulting firm has added the Aurix® System to its formulary. Founded in 2002, Wound Care Advantage (WCA) has established a large network of successful wound healing programs with partner hospitals. Through a strong commitment to quality care and innovation, WCA has built financially sustainable wound care programs that have saved limbs and lives of more than 40,000 patients suffering chronic wounds.